ACR
2017
ABSTRACT NUMBER: 1472 • 2017 ACR/ARHP Annual Meeting
Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio RegistryABSTRACT NUMBER: 1534 • 2017 ACR/ARHP Annual Meeting
Comparison of Long Term Anti-Tnf Survival in Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis; Data from Turkbio RegistryABSTRACT NUMBER: 1455 • 2017 ACR/ARHP Annual Meeting
Investigation of Poor Prognostic Factors Among Rheumatoid Arthritis Patients in Turkbio RegistryABSTRACT NUMBER: 542 • 2017 ACR/ARHP Annual Meeting
Is There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?2018
ABSTRACT NUMBER: 1547 • 2018 ACR/ARHP Annual Meeting
Impact of Obesity on Drug Survival of Tofacitinib in Patients with Rheumatoid Arthritis: Analysis from the Turkbio RegistryABSTRACT NUMBER: 542 • 2017 ACR/ARHP Annual Meeting
Is There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?ABSTRACT NUMBER: 2532 • 2018 ACR/ARHP Annual Meeting
The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio RegistryABSTRACT NUMBER: 2615 • 2018 ACR/ARHP Annual Meeting
The Effect of Smoking on Response to Tumour Necrosis Factor-Alpha Inhibitor Treatment in Psoriatic Arthritis Patients: Results from the Turkbio RegistryABSTRACT NUMBER: 1554 • 2018 ACR/ARHP Annual Meeting
Cigarette Smoking Does Not Affect Treatment Response to Tofacitinib in Rheumatoid ArthritisABSTRACT NUMBER: 2616 • 2018 ACR/ARHP Annual Meeting
The Effect of Smoking on Response to Tumor Necrosis Factor-Alpha Inhibitor Treatment in Ankylosing Spondylitis Patients: Results from the Turkbio RegistryABSTRACT NUMBER: 606 • 2018 ACR/ARHP Annual Meeting
Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
EULAR
2018
- Similar efficacy of tofacitinib on disease activity in rheumatoid arthritis patients with and without previous biologicals; results from the turkbio registry,
- Use of biological dmards in patients with primary vasculitis; results from turkbio registry,
- Comparison of long term anti-tnf survival in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis; data from turkbio registry,
- Investigation of poor prognostic factors among rheumatoid arthritis patients in turkbio registry,
- Concomitant use of corticosteroids at the baseline does not affect the drug survival of abatacept in rheumatoid arthritis,
- Is there any difference in ra patients for methotrexate use vs. leflunomide use as a concomitant treatment with biological and targeted synthetic dmards in turkbio registry?,
- Creation of a european database of patients with axial spondyloarthritis treated in clinical practice– initial, preliminary findings from the eurospa research network collaboration,
- The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases; results from the turkbio registry,
- Creating a european database of psoriatic arthritis patients treated in routine care – first, preliminary results from the eurospa research network collaboration,
- 2018 SAT0184 The effect of smoking on response to tumor necrosis factor-alpha inhibitor treatment in ankylosing spondylitis patients: results from the turkbio registry,
EUROSPA